Here are the Therapeutic potential of the flavonoid compound Licochalcone D in metabolic dysfunction-associated steatotic liver disease journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Monoclonal cd58 therapeutic potential, benefits of flavonoids as anticancer agents, monoclonal lmx1b therapeutic potential, biological activity of flavonoids, therapeutic potentials lakewood ranch, what are the benefits of flavonoids, what is flavonoids benefits, monoclonal dnajb4 therapeutic potential, monoclonal dnajb4 therapeutic potential, lsd is a potential therapeutic tool.
Therapeutic potential of the flavonoid compound Licochalcone D in metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent chronic liver disease associated with type 2 diabetes, which doubles the risk of developing this condition. Various flavonoid compounds have a positive effect on lipid metabolism, inflammation, and insulin resistance and can contribute to slowing down the progression of MASLD. In the current study, we investigated the biological effects of Licochalcone D (Lico D), a flavonoid, in a metabolic disease model. Oil Red O staining, quantitative real-time polymerase chain reaction, and western blotting were performed. For in vivo experiments, we used high-fat diet (60 %) plus low-dose streptozotocin (30 mg/kg; 5 days; intraperitoneal)-induced metabolic disease mouse model and evaluated lipid metabolism. We observed that Lico D reduced lipid accumulation and increased lipid metabolism both in vitro and in vivo. Additionally, we identified that the AMP-activated protein kinase and Sirtuin 1 pathways were a ctivated in the mouse liver and hepatic steatosis cell model. In silico analysis revealed that Lico D passes the "Lipinski Rule of Five," which indicates drug-likeness properties. In conclusion, our findings highlight the role of Lico D in improving metabolic dysfunction-associated steatotic liver disease. © 2024 Elsevier Inc.
Authors : Maharajan N.; Vijayakumar K.A.; Cho G.-W.
Source : Elsevier B.V.
Article Information
| Year | 2025 |
| Type | Article |
| DOI | 10.1016/j.bbrc.2024.151216 |
| ISSN | 0006291X |
| Volume | 744 |
You can download the article here
If You have any problem, contact us here